Rallybio director Hunt exercises 14,820 options

Q: How many Rallybio shares did director Ronald Hunt acquire through option exercises?

Ronald Hunt acquired 14,820 Rallybio common shares through option exercises on October 29, 2026, at exercise prices of $2.38, $7.60 and $15.28 per share.

A Rallybio director’s options carried three exercise prices; one option was issued in lieu of $51,500 in retainer fees.

Available on EDGAR 11/02/2026 - 05:17 PM EST Accepted by SEC EDGAR 11/02/2026 - 05:17 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Ronald Hunt, a director of Rallybio Corp, exercised options covering 14,820 common shares on October 29, 2026, and acquired the underlying shares. The options had exercise prices of $2.38, $7.60 and $15.28 per share. The option covering 9,196 shares was issued in lieu of $51,500 in retainer fees.

Insider Trade Summary

14,820 shares exercised/converted

Exercise 6 txns

Insider HUNT RONALD

Role Director

Type	Security	Shares	Price	Value
Exercise	Option (Right to Buy) ^F1	3,562	$0.00	$0.00
Exercise	Option (Right to Buy) ^{F3, F2}	9,196	$5.60	$51K
Exercise	Option (Right to Buy) ^F4	2,062	$0.00	$0.00
Exercise	Common Stock	3,562	$2.38	$8K
Exercise	Common Stock	9,196	$7.60	$70K
Exercise	Common Stock	2,062	$15.28	$32K

Holdings After Transaction: Option (Right to Buy) — 0 contracts (Direct); Common Stock — 14,820 shares (Direct)

Footnotes (4)

F1. The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders.
F2. The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.
F3. This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.
F4. The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders.

Key Figures

Derivative shares exercised: 14,820 shares Common shares acquired: 3,562 shares Common shares acquired: 9,196 shares +5 more

8 metrics

Derivative shares exercised 14,820 shares Reported aggregate for October 29, 2026

Common shares acquired 3,562 shares Option exercise on October 29, 2026; exercise price $2.38 per share

Common shares acquired 9,196 shares Option exercise on October 29, 2026; exercise price $7.60 per share

Common shares acquired 2,062 shares Option exercise on October 29, 2026; exercise price $15.28 per share

Exercise price $2.38 per share Option covering 3,562 common shares

Exercise price $7.60 per share Option covering 9,196 common shares

Exercise price $15.28 per share Option covering 2,062 common shares

Retainer fees $51,500 Amount for which the option covering 9,196 shares was issued in lieu

Key Terms

2021 Equity Incentive Plan, equal installments, retainer fees

3 terms

2021 Equity Incentive Plan technical

"granted under the Company's 2021 Equity Incentive Plan"

equal installments technical

"vests ... in 12 equal installments"

retainer fees financial

"in lieu of retainer fees of $51,500"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Rallybio shares did director Ronald Hunt acquire through option exercises?

Ronald Hunt acquired 14,820 Rallybio common shares through option exercises on October 29, 2026, at exercise prices of $2.38, $7.60 and $15.28 per share.

What were the vesting terms for Ronald Hunt’s Rallybio options?

The option covering 3,562 shares vested on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders. The option covering 9,196 shares vested in 12 equal installments, each on the last day of each month of calendar year 2025. The option covering 2,062 shares vested on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HUNT RONALD

(Last)

(First)

(Middle)

C/O RALLYBIO CORPORATION

PO BOX 325

(Street)

EAST BERLIN

CONNECTICUT

06023

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rallybio Corp [ RLYB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/29/2026		M		3,562	A	$2.38	3,562	D
Common Stock	10/29/2026		M		9,196	A	$7.6	12,758	D
Common Stock	10/29/2026		M		2,062	A	$15.28	14,820	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option (Right to Buy)	$2.38	10/29/2026		M			3,562	⁽¹⁾	05/13/2035	Common Stock	3,562	$0	0	D
Option (Right to Buy)	$7.6	10/29/2026		M			9,196	⁽²⁾	01/02/2035	Common Stock	9,196	$5.6⁽³⁾	0	D
Option (Right to Buy)	$15.28	10/29/2026		M			2,062	⁽⁴⁾	05/15/2034	Common Stock	2,062	$0	0	D

Explanation of Responses:

1. The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 13, 2026 or the date of the Company's 2026 Annual Meeting of Stockholders.

2. The option vests as to the underlying shares of Common Stock in 12 equal installments, each on the last day of each month of calendar year 2025.

3. This option was issued to the reporting person pursuant to the Company's 2021 Equity Incentive Plan in lieu of retainer fees of $51,500.

4. The option was granted under the Company's 2021 Equity Incentive Plan. The option vests on the earlier of May 15, 2025 or the date of the Company's 2025 Annual Meeting of Stockholders.

	By: /s/ Jonathan Lieber, Attorney-in-Fact	11/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR